Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) traded at $1.36 at last check on Friday, Nov 20, making a downturn move of -1.45% on its previous day’s price.
Looking at the stock we see that its previous close was $1.38 and the beta (5Y monthly) reads 2.02 with the day’s price range being $1.3400 – 1.3900. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, CATB has a high of $8.59 and a low of $1.25. The company’s stock has gained about -76.95% over that past 30 days.
Catabasis has a market cap of $25.76 Million and is expected to release its quarterly earnings report on November 12, 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the CATB stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.41, with the EPS growth for the year raised at -$1.96 for 2020 and -$0.86 for next year. These figures represent -0.17% and at -0.56% growth in EPS for the two years respectively.
On the other hand, looking at the outlook for the CATB stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 50% Sell.
Based on estimates by 3 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 3 have rated the Catabasis Pharmaceuticals, Inc. (CATB) stock as a Hold, while none rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Hold and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the CATB stock currently stands at 0, and the current price level is -24.76% off its SMA20 and -69.97% from its 50-day simple moving average. The RSI (14) is pointing at 19.83 while the volatility over the past week is 4.84% and jumps to 7.88% over the past one month. The beta value is 2.02, while the average true range (ATR) is currently pointing at 0.25. The average price target for the stock over the next 12 months is $17.75, with the estimates having a low of $11.5 and a high of $24. These price ends are 745.59% and +1664.71% off the current price level respectively, although investors could be excited at the prospect of a +1205.15% if the CATB share price touches on the median price of $17.75.
Let’s briefly compare Catabasis (CATB) stock to its peers. We find that today’s price change of -1.45% and -72.75% over the past 12 months for CATB competes that of Bristol-Myers Squibb Company (BMY), which has seen its stock price fall -0.77% in the latest trading session and is +8.37% over the last one year. Another of its peers Amgen Inc (AMGN) has dropped -0.67% today, but is -2.04% down over the past year, while Gilead Sciences Inc (GILD) is also down -1.45% yet its price remains in the red at -72.75% over the same period. Bristol-Myers has a P/E ratio of 0 compared to Catabasis 0 and Amgen’s 17.99. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -0.68% and -0.75%, respectively, in early deals.
Coming back to Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), we note that the average 3-month trading volume was 1.17 Million, while that of the preceding 10-day period stands at 1.4 Million. Current shares outstanding are 20.08 Million.
According to data from Thomson Reuters, insiders hold 0.13% of the company’s shares while institutions hold 43.58%. The data shows that short shares as of October 29, 2020, stood at 644.13 Million at a short ratio of 0.37. This represents a 3.38% Short interest in Shares outstanding on October 29, 2020. Shares short dropped in October from the previous month at 844.59 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -76.99% down in year-to-date price movement.